PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. The company is headquartered in San Jose, California and currently employs 888 full-time employees. The company went IPO on 2021-09-15. The firm is focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The firm's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
Mr. Larry Wood est le President de Procept Biorobotics Corp, il a rejoint l'entreprise depuis 2024.
Quelle est la performance du prix de l'action PRCT ?
Le prix actuel de PRCT est de $26.52, il a augmenté de 3.19% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Procept Biorobotics Corp ?
Procept Biorobotics Corp appartient à l'industrie Health Care et le secteur est Health Care
Quel est la capitalisation boursière de Procept Biorobotics Corp ?
La capitalisation boursière actuelle de Procept Biorobotics Corp est de $1.4B
Est-ce que Procept Biorobotics Corp est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 14 analystes ont établi des notations d'analystes pour Procept Biorobotics Corp, y compris 6 achat fort, 10 achat, 4 maintien, 0 vente et 6 vente forte
